RIYADH: The Saudi Heart Association has signed a memorandum of understanding with AstraZeneca to support cardiac research, train healthcare practitioners and improve care for hypertension patients, SPA reported on Friday.
The agreement comes as cardiovascular disease remains a major public health challenge in the Kingdom. Figures from the General Authority for Statistics show that 7.9 percent of people aged 15 and over had hypertension in 2024, while 1.5 percent had cardiovascular disease.
Cardiovascular diseases are disorders of the heart and blood vessels, including coronary heart disease and cerebrovascular disease, which affect the blood vessels supplying the heart and the brain, according to the World Health Organization.
Under the agreement, initial areas of cooperation include supporting the generation of scientific evidence through cardiology studies and research, and promoting scientific exchange through conferences and forums. The two sides will also build the capabilities of healthcare practitioners in cardiac specialties and work to improve care for hypertension patients by helping enhance the policies, quality, efficiency and pathways of cardiac care in the Kingdom.
Dr. Waleed Al-Habeeb, president of the association and a consultant heart failure cardiologist at King Saud University, said improving heart disease treatment outcomes in the Kingdom required coordinated and ambitious work across the healthcare system.
He added that the partnership with AstraZeneca would strengthen the association’s ability to generate scientific…



